QIAGEN

QIAGEN N.V. to release results for Q1 2024 and hold webcast

Retrieved on: 
Tuesday, April 9, 2024
Webcast, QIA, Conference, Conference call, QGEN, Frankfurt Stock Exchange, QIAGEN

Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024.

Key Points: 
  • Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024.
  • Press release date / time: Monday, April 29, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
  • Conference call date / time: Tuesday, April 30, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.
  • Access the audio webcast - Click here: Access Webcast
    A conference call replay will be available by using the following link:

QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024

Retrieved on: 
Wednesday, April 3, 2024
EGFR, Gene, Nested polymerase chain reaction, Professor, Cancer Institute, Circulating free DNA, Neoplasm, TCR, Research institute, QGEN, Research, PCR, Central business district, NGS, DNA, BRAF, Diagnosis, WIA, Cancer, Immune system, Liquid biopsy, UMI, Mutation, Genetics, Human genetics, Senior, AACR, Medical school, QIAGEN, Poster, Environment, IVD, Urine

Two Exhibitor Spotlight Theater sessions and several poster presentations will highlight additional advances from QIAGEN in this field.

Key Points: 
  • Two Exhibitor Spotlight Theater sessions and several poster presentations will highlight additional advances from QIAGEN in this field.
  • EGFR and BRAF are genes essential for normal cell growth and function, but mutations in these genes can result in cancer development.
  • To advance research on how the immune system interacts with cancer, QIAGEN has introduced the QIAseq Targeted RNA-seq Panel for T-cell receptors.
  • Learn more about QIAGEN’s offering at the AACR Annual Meeting 2024, (booth #922 in the San Diego Convention Center) and poster presentations highlighting new solutions in digital PCR, NGS and preanalytical workflows at https://www.qiagen.com/applications/cancer-research/aacr-2024-annual-mee... .

QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system

Retrieved on: 
Monday, March 25, 2024
PCR, Comment, Patient, Software, Epidemiology, RAM, Senior, QIAGEN, QGEN, Medical device

The upgraded diagnostic system, powered by the new QIAstat-Dx Operational Module PRO with a 64‑bit processor and 4GB of RAM, introduces the Remote Results Application, still unique in the syndromic testing space.

Key Points: 
  • The upgraded diagnostic system, powered by the new QIAstat-Dx Operational Module PRO with a 64‑bit processor and 4GB of RAM, introduces the Remote Results Application, still unique in the syndromic testing space.
  • The new feature, accessible through the QIAsphere cloud and exclusively available with QIAstat‑Dx Analyzer 2.0, allows users to view, comment and confirm diagnostic test results directly from their desktop and mobile devices in any location, facilitating seamless collaboration across the healthcare system.
  • This enables greater flexibility and collaboration between central and regional labs, especially in decentralized testing, reducing diagnostic processing time and ensuring patients receive accurate results more quickly.
  • Alternatively, the QIAstat-Dx Analyzer 2.0 enables in-house visibility of test results over a shared network.

QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements

Retrieved on: 
Monday, March 18, 2024
BCG, IGRA, Disease, Infection, Tuberculosis, World Tuberculosis Day, Incidence, Partnership, Molecular diagnostics, Interferon gamma release assay, CPD, Patient, Ageing, Epidemiology, Genetically modified bacteria, Senior, TST, IPPA, MPH, CDC, Vaccination, QIAGEN, Gold, WHO, TB, Physician, QGEN

Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements.

Key Points: 
  • Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements.
  • A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers.
  • This collaboration follows the U.S. Centers for Disease Control and Prevention (CDC) updating its guidelines for new TB screening requirements for immigrants to the United States.
  • Alexandra Ortega, MPH, MCHES, Executive Director of the IPPA, said, “Working together with QIAGEN allows us to educate panel physicians on the latest TB screening requirements, ensuring patients receive the most accurate and efficient testing available.

DNA Methylation Detection Technology Market Research 2024 - Global Forecast to 2033 Featuring Prominent Players - Thermo Fisher Scientific, Illumina, QIAGEN, Zymo Research, and Agilent Technologies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Genetics, Health, Diagnosis, PCR, Growth, Drug discovery, Thermo Fisher Scientific, Biomarker, Research, DNA, Competitive landscape, Real-time, Microarray, Cancer, Software, DNA methylation, Agilent Technologies, DSM-IV codes, QIAGEN, MSP, Prognosis, Marketing, Medicine, Fine chemical

The global DNA methylation detection technology market is projected to experience substantial growth over the forecast period 2023-2033.

Key Points: 
  • The global DNA methylation detection technology market is projected to experience substantial growth over the forecast period 2023-2033.
  • In the DNA methylation detection technology market, several key players dominate the landscape with their diverse range of products and solutions.
  • Thermo Fisher Scientific, Illumina, Inc. QIAGEN, Zymo Research Corporation, and Agilent Technologies, Inc. are among the prominent market players offering innovative tools and platforms for DNA methylation analysis.
  • The global DNA methylation detection technology market can be considered to be in the mature growth stage of its lifecycle.

MyBio Are the New Exclusive Partner for QIAGEN in Ireland & Northern Ireland

Retrieved on: 
Wednesday, March 27, 2024
Research, Public Policy, Government, Other Natural Resources, Biotechnology, White House, Federal Government, Health, Agriculture, Natural Resources, Science, Other Science, Partnership, HID, RNA, DNA, IVD, QDI, Protein, QIAGEN, Collection, Marketing

MyBio Ltd., an award-winning specialist Irish life science distribution partner, announces a new exclusive partnership with QIAGEN, a leading global provider, to distribute their leading Life Science “Sample to Insight” product range throughout Ireland and Northern Ireland with effect from April 1st, 2024.

Key Points: 
  • MyBio Ltd., an award-winning specialist Irish life science distribution partner, announces a new exclusive partnership with QIAGEN, a leading global provider, to distribute their leading Life Science “Sample to Insight” product range throughout Ireland and Northern Ireland with effect from April 1st, 2024.
  • This exclusivity refers to Life Science products for the respective customer base and does not extend to other product portfolios of QIAGEN such as IVD regulated products, HID, Instrument Service or QDI products or customer segments.
  • This new partnership extends QIAGEN’S reach into the Irish life science market by leveraging MyBio Ltd.’s strong commercial presence and deep ties within the Academic, Biopharma and Agri-Bioscience industries in Ireland and Northern Ireland.
  • Under the terms of the agreement, MyBio Ltd. will exclusively supply the QIAGEN Life Science research product range to the academic research, biopharma, and agri-bioscience industries across the Island of Ireland.

North America Molecular Diagnostics Market Size, Share & Trends Analysis Report 2024-2030: Growing Prevalence of Target Diseases & Increasing External Funding for R&D Fueling Expansion - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2024
Health, Biotechnology, Candidiasis, Diagnosis, PCR, MVP, Conditional sentence, Bacterial vaginosis, Prevalence, Infection, Promega, Country, Thermo Fisher Scientific, SME, Tuberculosis, Application, ISH, RT, HIV, Alzheimer's disease, Incidence, Turner syndrome, Cepheid variable, Research, Trichomoniasis, Real-time, Cancer, Death, Parkinson's disease, CDC, QIAGEN, Therapy, USD, Horvitz–Thompson estimator, Helix, DSM-IV codes, Vaccine

Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens.

Key Points: 
  • Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens.
  • Molecular diagnostics enable early diagnosis of cancer, genetic disorders, and infectious diseases by using PCR, sequencing, & genetic technologies.
  • In addition, the increasing incidence of diseases, such as influenza A & B, is projected to drive market growth.
  • An increase in external funding to conduct clinical studies in molecular diagnostics is anticipated to fuel the market.

DNA Methylation Detection Technology Markets, 2033 - Intensified Competition, Increasing Adoption, PCR Dominates

Retrieved on: 
Saturday, March 30, 2024
Diagnosis, PCR, Health, Growth, Biotechnology, Drug discovery, Thermo Fisher Scientific, Biomarker, Research, DNA, Competitive landscape, Real-time, Microarray, Cancer, Software, DNA methylation, Agilent Technologies, DSM-IV codes, QIAGEN, MSP, Prognosis, Marketing, Medicine, Fine chemical

In the DNA methylation detection technology market, several key players dominate the landscape with their diverse range of products and solutions.

Key Points: 
  • In the DNA methylation detection technology market, several key players dominate the landscape with their diverse range of products and solutions.
  • Based on technology, the PCR segment accounted for the largest share of the global DNA methylation detection technology market in FY2022.
  • Moreover, PCR is expected to maintain its dominance in the global DNA methylation detection technology market by technology due to its widespread adoption, versatility, and reliability.
  • Based on application, diagnostic research accounted for the largest share of the global DNA methylation detection technology market in FY2022, primarily due to clinicians' increasing focus on utilizing DNA methylation analysis for clinical diagnostics.

DNA Sequencing Market Projected to Reach $210.34 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Friday, March 22, 2024
Genomics, Computational biology, Growth, Prevalence, Consumables, Intelligence, DSM-IV codes, Workflow, NGS, DNA, Cancer, Medicine, Nucleotide, Agilent Technologies, Investment, QIAGEN, Safety, Sanger sequencing, Disorder, Table, Vaccine

DNA sequencing, a pivotal laboratory process that determines the order of nucleotides in DNA, has become crucial in diagnosing and treating diseases, medical research, and forensic studies.

Key Points: 
  • DNA sequencing, a pivotal laboratory process that determines the order of nucleotides in DNA, has become crucial in diagnosing and treating diseases, medical research, and forensic studies.
  • However, the DNA sequencing market faces hurdles, including technical constraints, high costs, and the complexity of data interpretation, which impede broader adoption.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the DNA Sequencing Market.
  • "Dive into the DNA Sequencing Market Landscape: Explore 196 Pages of Insights, 562 Tables, and 24 Figures"

DNA Sequencing Market Projected to Reach $210.34 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Friday, March 22, 2024
Genomics, Computational biology, Growth, Prevalence, Consumables, Intelligence, DSM-IV codes, Workflow, NGS, DNA, Cancer, Medicine, Nucleotide, Agilent Technologies, Investment, QIAGEN, Safety, Sanger sequencing, Disorder, Table, Vaccine

DNA sequencing, a pivotal laboratory process that determines the order of nucleotides in DNA, has become crucial in diagnosing and treating diseases, medical research, and forensic studies.

Key Points: 
  • DNA sequencing, a pivotal laboratory process that determines the order of nucleotides in DNA, has become crucial in diagnosing and treating diseases, medical research, and forensic studies.
  • However, the DNA sequencing market faces hurdles, including technical constraints, high costs, and the complexity of data interpretation, which impede broader adoption.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the DNA Sequencing Market.
  • "Dive into the DNA Sequencing Market Landscape: Explore 196 Pages of Insights, 562 Tables, and 24 Figures"